Screener
Savara SVRA Nebulizer — Contingent Milestone Payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Savara in its filing.
Tagged under the XBRL concept svra:ContingentMilestonePayments.
The source filing: Savara’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219371
| GEMA: | |
| Achievement of certain milestones related to validation of API supplied by GEMA and regulatory approval of MOLBREEVI drug substance produced at GEMA | $200 |
| PARI: | |
| Achievement of various development activities and regulatory approval of proprietary nebulizer utilized to administer MOLBREEVI | 573 |
| Total manufacturing and other commitments and contingencies | $773 |
Cover / Front Matter
FAQ
- What is Savara's nebulizer — contingent milestone payments?
- Savara (SVRA) reported nebulizer — contingent milestone payments of $573K in Q1 2026.
- How has Savara's nebulizer — contingent milestone payments changed year-over-year?
- Savara's nebulizer — contingent milestone payments increased by 5.9% year-over-year, from $541K to $573K.
- What does nebulizer — contingent milestone payments mean?
- Represents the total value of payments triggered by the achievement of specific clinical, regulatory, or commercial development milestones related to the nebulizer product line. These payments reflect the financial obligations associated with the progression of the drug development lifecycle. Monitoring these payments helps investors assess the cost of advancing the product toward market authorization.
Ask your AI about Savara's nebulizer — contingent milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude